Myelodysplastic Syndromes (MDS) Market Outlook

Thelansis’s “Myelodysplastic Syndromes (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelodysplastic Syndromes treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Myelodysplastic Syndromes (MDS) Overview

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell disorders characterised by ineffective haematopoiesis, peripheral blood cytopenias, dysplastic bone marrow morphology, and variable risk of transformation to acute myeloid leukaemia. Somatic mutations in splicing factor genes — SF3B1, SRSF2, U2AF1 — epigenetic regulators including TET2, DNMT3A, and ASXL1, and transcription factors such as RUNX1 alongside cytogenetic aberrations — deletion 5q, monosomy 7, and complex karyotype — drive clonal evolution and disease progression. Patients present with symptomatic anaemia, fatigue, recurrent infections, and bleeding tendency; diagnosis integrates bone marrow biopsy demonstrating dysplasia in one or more cell lineages, cytogenetic analysis, and comprehensive somatic mutation profiling. Risk stratification employing IPSS-R and molecular IPSS-M incorporating mutational data guides therapeutic intensity. Transfusion-dependent anaemia in lower-risk MDS with SF3B1 mutation benefits from luspatercept — an erythroid maturation agent — while lenalidomide addresses deletion 5q disease. Hypomethylating agents — azacitidine and decitabine — are cornerstones of higher-risk MDS management, with enasidenib and ivosidenib targeting IDH2 and IDH1 mutations respectively in eligible patients. Allogeneic stem cell transplantation remains the only potentially curative option for eligible higher-risk patients. Prognosis varies considerably with risk category; regular haematological monitoring, transfusion support, iron chelation, and patient-centred goals-of-care discussions are integral to compassionate long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)